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Breast cancer is a serious threat worldwide and is the number two killer of women in the United States. The key to successful
management is screening and early detection. What follows is a description of the state of the art in screening and detection for
breast cancer as well as a discussion of new and emerging technologies. This paper aims to serve as a starting point for those who
are not acquainted with this growing ﬁeld.
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1.Introduction
Breast cancer is the most common form of cancer among
women and the second most common cancer in the world
(an estimated 1152161 new cases per year), trailing only
lung cancer [1]. In 2009, an estimated 40610 people (men
and women) were projected to die of breast cancer in the
United States [2]. The current approach to this disease
involves early detection and treatment. This approach in the
United States yields an 85% 10-year survival rate. Survival
is directly related to stage at diagnosis, as can be seen by
a 98% 10-year survival rate for patients with stages 0 and
I disease compared with a 65% 10-year survival rate for
patients with stage III disease. To improve survival in this
disease, more patients need to be identiﬁed at an early stage.
Therefore, we evaluated existing and emerging technologies
used for breast cancer screening and detection to identify
areas for potential improvement. The main criteria for a
good screening test are accuracy, high sensitivity, acceptable
speciﬁcity, ease of use, acceptability to the population being
screened (with regard to discomfort and time), and low
cost. This paper begins by describing commonly used breast
cancer detection techniques and then delves into emerging
modalities.
2. Commonly Used Methods
2.1. Breast Self-Examinations, Clinical Breast Examinations,
and Mammography. Breast self-examination (BSE) and clin-
ical breast examination (CBE) are used to screen for breast
cancer. CBE has a sensitivity of 57.14% and a speciﬁcity
of 97.11% [3]. Although it does not permit one to deter-
mine malignancy with assurance, it is useful for detecting
suspicious breast lesions. Kosters and Gotzsche [4]f o u n d
no improvement in breast cancer mortality rates in those
screened using BSE and CBE compared with those with
no screening, although those screened underwent twice as
many biopsies. Despite these results and those from similar
studies, some believe that CBE and BSE should still be used,
especially for women younger than 40 years as well as for
thosewhodonotundergoroutinemammography[5].Other
studies indicate that many teachers and nurses, that is, those
who inﬂuence young women, are not ﬂuent in BSE, either
because they are uneducated on the subject or because they
fail to perform it correctly [6]. In one study, 99% of nurse
participants felt capable of performing a BSE, yet only 26%
performed a monthly BSE [7]. A deﬁnite need exists to
improve our ability to teach and validate BSE and CBE so
that these methods can be used eﬀectively for screening.2 International Journal of Biomedical Imaging
Generally referred to as the gold standard of breast imag-
ing, mammography, or screen-ﬁlm mammography (SFM),
is the most common form of breast imaging. It is basically
an X-ray examination of the breast under compression.
It has a true-positive rate of 83% to 95% and a false-
positive rate of 0.9% to 6.5% (note, however, that these
ﬁgures stem from meta-analysis, which uses an idealized
population of 27% young women, while the false-positive
rate in young women is known to be higher) [8]. Sensitivity
and speciﬁcity of mammography are aﬀected by breast
density, which in turn is aﬀected by “age, use of hormone
replacement therapy (HRT), menstrual cycle phase, parity,
body mass index, and familial or genetic tendency” [8, 9].
In one study, sensitivity was 68.6% in women aged 40 to
44 and 83.3% in women aged 80 to 89; whereas speciﬁcity
values (in women who did not use hormone replacement
therapy) were 91.4% and 94.4%, respectively [9]. In that
study, the results from women of all ages who used hormone
replacement therapy yielded a mammographic speciﬁcity of
about 91.7% [9]. Mammography is less sensitive in women
with radiographically dense breasts. Sensitivity values range
from 62.9% in extremely dense-breasted women to 87% in
extremely fatty-breasted women, whereas speciﬁcity values
ranged from 89.1% to 96.9%, respectively [9].
Mammograms have certain limitations. They require a
dedicated machine, radiographic ﬁlm and developing chem-
icals, a trained X-ray technologist, and a radiologist to read
the ﬁlms. They require breast compression, which causes
the patient discomfort. Images seen on mammograms also
lead to unnecessary biopsies. A study showed that biopsies
of microcalciﬁcations seen on mammograms yielded only
36.5% containing malignant tissue [10]. The process also
exposes the breast to radiation, a “mean glandular dose
from 2-view mammography of approximately 4 to 5mGy”
[11], which may cause radiation carcinogenesis. Despite this
hazard, the beneﬁts of a mammogram outweigh the risks
[12]. As a screening modality, SFM remains the current
standardfordetectingbreastcancer.Thetechnologyhasbeen
in place for more than 30 years, and the images are widely
accepted as standard in clinical use. Still, newer technologies
may prove more favorable than mammography, and much
researchfocusesonobtainingbettersystemsforbreastcancer
detection.
2.2.Full-FieldDigitalMammography. Full-ﬁelddigitalmam-
mography (FFDM) is simply a digital mammogram. Rather
than recording an image on ﬁlm, FFDM records an image
in an electronic ﬁle. Mammography is divided into discrete
processes: image acquisition, image display, and image
storage, so each can be optimized separately [13]. FFDM
allows real-time image presentation, postimage processing,
and digital storage [14, 15]. Digital mammographic images
can be transmitted electronically (e.g., via the Internet) in
a process known as telemammography [13], allowing the
radiologist and the clinician to review the images from a
remote location. The machines are 10 to 40 times more
expensive to buy than ﬁlm screen mammography units
but yield a cost savings by removing the need for ﬁlm
and developing chemicals as well as reducing the need
for call backs to bring patients back due to poor image
quality. FFDM does have disadvantages. It has poorer spatial
resolutionthanﬁlmmammography,anditsﬁlesrequirelarge
amounts of digital storage space [15].
Cancer detection rates using FFDM or SFM are basically
equal [16, 17], but FFDM allows better classiﬁcation of
lesions through the Breast Imaging Reporting and Data
System (BI-RADS). One study found the sensitivity and
speciﬁcity for FFDM to be 95.2% and 41.4%, respectively,
in comparison to those for SFM, which were 91.9% and
39.3% [14]. A large-scale comparison study (over 40000
participants), the Digital Mammographic Imaging Screening
Trial (DMIST), by Pisano et al. [18] concluded that FFDM is
more accurate in “women under the age of 50 years, women
with radiographically dense breasts, and premenopausal or
perimenopausal women.”
2.3. Computer-Aided Detection (CAD). C A Di sp a t t e r n
recognition software that identiﬁes suspicious abnormalities
on images, marking them for the radiologist. CAD also
stands for computer-aided diagnosis, which refers to a
system that marks benign or malignant images, and the two
acronyms are often confused. The most popular CAD system
is the R2 Image Checker (R2 Technology, Inc., Santa Clara,
CA), which combines detection and diagnosis [15].
The Food and Drug Administration requires radiologists
to review and interpret FFDM data before seeing CAD
marks [19]. Furthermore, because CAD does not mark all
suspiciousareas,radiologistsmustnotdisregardﬁndingsnot
alsofoundbyCAD[19].Also,becauseCADshowsmorefalse
than true CAD marks, the radiologist must decide which
marks are correctly placed [19]. In one study, 97.4% of CAD
marks were rejected by the radiologist [20].
In a retrospective study done in 2000, radiologists had a
false-negative rate of 21%, which could have been reduced
by 77% with the use of CAD [21]. Freer and Ulissey [20]
found that the introduction of CAD increased the recall rate
from 6.5% to 7.7%, the number of cancers found by 19.5%,
and the number of early-stage malignancies from 73% to
78%. This study also showed that CAD and radiologists had
about the same accuracy: CAD detected 40 of 49 lesions,
whereas the radiologist detected 41 of 49 lesions [20]. Brem
et al. [22] found that CAD was more accurate in detecting
microcalciﬁcations than masses. She and her colleagues also
found that CAD had high sensitivities for ductal carcinoma
in situ (DCIS) and invasive lobular carcinoma. CAD systems
have been in clinical use since 2000 and can be used
directly on digital mammography ﬁles or on scanned SFM
ﬁlms. CAD can also be applied to other images such as
those generated by computed tomography, ultrasound, and
magnetic resonance imaging.
2.4. Modalities Using Ultrasound. Ultrasonography (US),
also known as sonomammography, is frequently used to
image palpable masses in the breast or as a follow-up test for
abnormal results on a mammogram. The current technology
involves a handheld transducer placed on the breast surface
by a technologist and moved around to image the breastInternational Journal of Biomedical Imaging 3
below the transducer. The images obtained must be labeled
by the technologist in regard to location in the breast and
orientation. A slight change in orientation of the beam may
miss an area or image it twice, making US an operator-
dependent modality. Lastly, the usual probe is 1cm by 6cm,
which makes it diﬃcult to cover the entire surface of a breast
in a reliable fashion for screening.
2.4.1. B-Mode Ultrasound. The most common form of
ultrasound, B-mode, uses sound waves bounced oﬀ tissues
to create an image of the breast. The strength of each
echo determines the brightness of that point. From these
echoes, two-dimensional images are created, generally about
30 images per second, allowing for real-time imaging [23].
Various tissues can be identiﬁed by brightness and image.
Ultrasound is most often used to characterize lesions, to
identify palpable masses that cannot be seen on mam-
mograms, and to examine women not able to undergo
mammography: the young and the pregnant [23]. It is
also suitable for scanning dense breasts. B-mode ultrasound
is also used to guide biopsies. Computer-aided diagnosis
technology can be applied to US yet causes the loss of the
real-time analysis that makes US so popular [23].
US is generally not used for screening, although some
studiesindicateotherwise.AstudybyKolbetal.[24]showsa
17% increase in overall cancer detection and a 37% increase
in tumors detected by imaging when US was added to
a mammographic screening. A study by Rahbar [25]a n d
colleagues indicates that US can aid in the diﬀerentiation
between benign and malignant masses based on the shape
of the mass’s image. Simple cysts are diagnosed with 98%
to 100% accuracy, yet more complex cysts yield a lower
sensitivity [23]. Unfortunately, B-mode ultrasonographic
images contain speckle and clutter, lowering the image
quality [23, 26]. Also, lesion lateral margins are diﬃcult to
detect [23].
2.4.2. Compound Imaging. Compound imaging combines
multiple US images into one, decreasing the amount of
speckle, clutter, noise, and shadowing, yielding a higher
quality, “smoother,” image [23, 26, 27]. Compound imaging
improves tissue diﬀerentiation, margin visualization, inter-
nal architecture visualization, and low-contrast lesion con-
spicuity, creating a more realistic image [26, 27]. Although
better in quality than B-mode US, compound imaging is
subject to blurring, and it suppresses shadows that can be
used to determine malignancy [23].
2.4.3. Doppler Ultrasonography. Doppler US uses the
Doppler eﬀect to track blood ﬂow, ﬁnding malignant tumors
through their neoangiogenesis. Two types of Doppler
ultrasound exist: color and power, though power Doppler
ultrasound is better for tracking intralesional blood ﬂow
[15, 28]. Cosgrove et al. [29] found that 99% of malignant
lesions contained blood vessels and that 96% of benign
lesions showed no color Doppler marks, indicating that
color Doppler marks should warrant a biopsy. Despite
this study and that of Raza and Baum [30], who found
68% sensitivity, 95% speciﬁcity, 85% positive predictive
value, and 88% negative predictive value, other studies
have reported less favorable views of Doppler US [23, 28].
Doppler US can be enhanced using microbubble-based
contrast agents. Although regular Doppler US cannot depict
blood vessels smaller than 100 to 200μm, smaller vessels can
be seen with contrast enhancements, though various studies
on the subject report conﬂicting results [23]. One study
shows an increase in sensitivity from 36% to 95%, positive
predictive values from 67% to 78%, and negative predictive
values from 63% to 96%, although speciﬁcity decreased
from 86% to 79% when Doppler was added to conventional
sonography [31].
2.5. Magnetic Resonance Imaging (MRI). MRI can create
either 2- or 3D images, which, depending on the acquisition
style, static or dynamic, have tradeoﬀs between spatial and
temporal resolution [32, 33].
Magnetic resonance imaging uses a magnetic ﬁeld (gen-
erally 1.0–1.5T) and radio waves to change the alignment
of hydrogen nuclei and, from this change, creates an image.
A gadolinium-based contrast agent is commonly used in
breast imaging [15, 33]. The subject lies prone, while
either one or both breasts, depending on the type of coil,
are imaged [33, 34] .W h e r e a sm a m m o g r a p h yw o r k sb e s t
with fatty breasts, fat must be suppressed in MRI, either
through postprocessing subtraction or other techniques
before contrast agent injection, to preserve the image quality
[33].
The sensitivity of MRI in visualizing invasive cancer
is nearly 100%, yet speciﬁcity values vary [33]. A study
investigating preoperative imaging techniques found that
MRI had a detection rate comparable to that of US (which
is unaﬀected by tumor size in either case) and a sensitivity
rate higher than that of both mammography and US [33].
Also, MRI can better detect intraductal spread than can US
ormammography[35].MRIalsoshowspromiseinscreening
women with familial or genetic predispositions to breast
cancer [36]. Results of these two studies can be found in
Table 1.
With respect to DCIS, the sensitivity of MRI ranges from
40% to 100%, with some authors reporting less sensitivity
than mammography. With respect to invasive lobular carci-
noma, sensitivity is 93.3% (through meta-analysis), with a
correlation with pathologic abnormalities ranging from 0.81
to 0.97 [37], making it more sensitive than mammography.
In correlation with mammography, MRI yielded a sensitivity
rate of 88.1% and a speciﬁcity of 67.7% prior to biopsy
in a study by Bluemke and colleagues [38]. This study
also corroborated the results of the aforementioned studies,
ﬁndinggreatersensitivitywithrespecttoinvasivecancerthan
DCIS.
Whereas US-guided biopsies are easy, MRI-guided biop-
s i e sa r em o r ed i ﬃcult, requiring special MR-compatible
e q u i p m e n ts u c ha sn e e d l e s[ 33]. Also, with MRI, the
lateral side of the breast is the only accessible side in
most systems [33]. It is diﬃcult to ensure the removal of
the lesion [33] using needle-based techniques compared4 International Journal of Biomedical Imaging
Table 1: Comparative studies of detection techniques. CBE: clinical breast examination; MRI: magnetic resonance imaging; US:
ultrasonography.
Study Value CBE Mammography (%) US (%) MRI (%)
Preoperative evaluation [35]
Detection rate — 84.6 97.3 93.7
Sensitivity — 22.2 20.6 66.7
Speciﬁcity — 85.7 85.2 64.2
Accuracy of
intraductal spread
— 50.0 50.0 65.6
Screening in women with familial
or genetic predisposition [36]
Sensitivity 17.9 33.3 — 79.5
Speciﬁcity 98.1 95.0 — 89.8
with conventional mammogram- or ultrasound-guided
biopsies.
MRI is the best technique for postchemotherapy imag-
ing. Accuracy may vary with the degree of response to
chemotherapy [32, 39]. A study by Partridge et al. [40]
found a correlation with pathologic abnormalities of 0.89
for MRI and 0.60 for clinical measurements, conﬁrming the
value of the use of MRI in patients who have undergone
neoadjuvant chemotherapy. The MRI technique is also
sensitive in imaging silicone breast implants. A study found
that the rates of sensitivity and speciﬁcity for detection of
silicone implant rupture were 76% and 97%, respectively,
making it superior to mammography and ultrasonography
for that indication [34]. MRI has better resolution and less
operator dependence than US [33]. Also, it does not use
radiation, making it safer than those modalities that do,
thus allowing use with pregnant patients, although the eﬀect
of contrast media on the fetus is not known [33]. On the
other hand, MRI is costly, without a clear notion of cost
eﬀectiveness [33]. Its contrast agent can also aﬀect benign
lesions [33].
One must note the paucity of standardized indications
for MRI use, procedure protocol, or interpretation [33]. Orel
[39] states that MRI “should never be used in place of a
full mammographic and sonographic evaluation”. Lalonde
et al. [41] advise that “MRI should not be used to decide
whether a lesion seen on conventional imaging should
undergo a biopsy” and that MRI should not be used to
categorize a lesion as BIRADS 3 or 4, meaning probably
benign or suspicious, respectively. A recent study indicated
that the routine use of MRI in women already identiﬁed as
having breast cancer increased the detection of synchronous
disease [42]. Although commonly used to screen high-risk
populations, as we gain more clinical experience with MRI,
its role in diagnosis is becoming clearer, and the likelihood
that it will be a successful general screening modality is
decreasing.
2.6. Nuclear Medicine. Nuclear medicine techniques yield
functional images based on molecular properties. They do
not have unfavorable eﬀects stemming from breast density
[15]. Also, these techniques require little or no breast
compression.Nuclearmedicinetechniquesareexpensiveand
expose the patient to radiation yet show promise in detecting
cancer, especially in high-risk patients.
2.6.1. Radioimmunoscintigraphy. In radioimmunoscintigra-
phy (RIS), tumor-associated antigens are targeted by an
injected radiopharmaceutical agent [43, 44]. Identiﬁcation
is based on diﬀerences in antigen expression in normal
and cancer cells. Although earlier work used 131Ia n d111In,
the most commonly used label today is 99mTc. Antigens
targetedbythistechniqueincludecarcinoembryonicantigen,
polymorphic breast epithelial mucin antigen, and TAG72
antigen [44]. It can also be used for receptor imaging, using
somatostatinreceptors[44].RIScanalsobeperformedusing
perfusion agents, including thallium-201, 99mTc-sestamibi,
99mTc-tetrofosmin, 99mTc-methylene diphosphonate, and
99mTc-diethylene triamine penta-acetic acid [15, 43]. RIS
is associated with high cost and with moderate rates of
sensitivity and speciﬁcity, indicating that it is not a good
screening method [44].
2.6.2. 99m-Tc-Sestamibi Scintimammography. Because of its
strong attraction to the negatively charged mitochondria,
the lipophilic 99mTc-hexakis-2-methoxy isobutyl isonitrile
molecule has become widely used in scintimammography
[44]. Its uptake “is due to an increase in blood ﬂow, number
of mitochondria and cancer cell membrane hyperpolariza-
tion in the tumor and as a function of the expression of
the multidrug resistance gene” [43]. The technique of 99m-
Tc-sestamibi scintimammography (SMM) is best performed
“before or after 7–10 days after ﬁne needle aspiration,
4–6 weeks after breast biopsy and at least 2-3 months
after breast surgery or radiotherapy” [44]. A multicenter
study conducted by Sampalis et al. [45] found sensitivity,
speciﬁcity, positive predictive, and negative predictive values
related to SMM of 93%, 87%, 58%, and 98%, respectively.
Similarly, a meta-analysis of 64 unique studies published
between 1967 and 1999 yielded a sensitivity of 85.2%
and a speciﬁcity of 86.6% [46]. A comparison of SMM
to MRI found that SMM had a higher speciﬁcity than
MRI, indicating that it could be used clinically to evaluate
lesions larger than 1cm in diameter [47]. A comparison
with sonography found that the negative aspects of SMM
overshadowed its high detection accuracy, indicating that it
probablywillnotreplacesonography[48].AstudybyCwikla
and colleagues [49] found that SMM detected more cases of
multifocalandmulticentriccancerthanbothmammography
and ultrasonography. A study by Hillner [50] estimated that
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decrease costs by 39% and result in 65% of women avoiding
biopsy. Khalkhali and Itti [51] recommended SMM for
primary cancer detection in patients with dense breasts
and in high-risk patients with no abnormalities found by
mammography and CBE, detection of cancer recurrence,
monitoring response to neoadjuvant chemotherapy, and
radionuclide-guided prebiopsy.
SMM, however, takes longer to perform than US and
subjects the patient to ionizing radiation [48]. The technol-
ogy is associated with a high rate of false-positive responses
[46,48]andlowsensitivityforsmallcancers(<1–1.5cm)and
DCIS [51].
Planar and single-photon emission computed tomog-
raphy (SPECT) are methods used to image the aforemen-
tioned radiopharmaceuticals agents. Planar imaging uses a
conventional gamma camera to create a 2D image [43].
SPECT uses multiple planar images taken at diﬀerent angles
to reconstruct a 3D image [43]. In fact, a SPECT system
dedicated solely to breast imaging has been developed [52].
2.6.3. Positron Emission Tomography. Positron emission
tomography (PET), generally using 18F-ﬂuorodeoxyglucose
(18F-FDGorsimplyFDG),usesglucosemetabolismtodetect
cancer. This radiotracer has a high lesion-to-background
ratio [53]. FDG-PET has a well-established track record for
the detection of malignancy, especially metastatic disease
in solid organ tumors. PET can also measure methionine
metabolism, using L-methyl-11C-methionine, and hormone
receptors, using 16-18ﬂuoroestradiol 17β [44]. Another
radiotracer, 18F-ﬂuoro-L-thymidine (FLT), has been used to
measurethymidinekinase-1activity,whichisassociatedwith
S-phase DNA synthesis [54] .F L Tu p t a k ei sl e s ss e n s i t i v e
to inﬂammation caused by needle biopsy, providing an
advantage in similar situations [54].
Imaging generally occurs 40 to 60 minutes after injection
[55], yet Boerner et al. [56] showed that waiting longer
increases the detection rate. It has also been found that
PET imaging in the prone position with the aid of a breast
positioning device improves the modality’s cancer detection
rate [57]. PET is useful in follow-up examinations, scanning
the entire body for recurrence; Lind and colleagues [55]
found an average sensitivity of 96% and speciﬁcity of 77%
in their study. Like SMM, PET has diﬃculties detecting small
primary cancers [58], making it unlikely to become a useful
screening modality.
3. ExperimentalTechniques
3.1. Advanced Applications of Digital Mammography. In
addition to CAD, the ability of FFDM to detect lesions can
be improved in a number of ways. We discuss tomosynthesis
and contrast-enhanced digital mammography.
3.1.1. Tomosynthesis. In tomosynthesis, multiple images (at
least eight) are obtained using FFDM while the X-ray
t u b ec h a n g e sa n g l e s[ 59]. In some types of tomosynthesis,
the detector remains in place (yielding a more restricted
view); whereas in others, the detector follows in rotation.
Exposures are made as the angle changes. Each exposure
is done with a low dose (each about 10% of a normal
mammogram), either taken in a step-and-shoot method
or in a continuous method involving X-ray pulses [60].
As the X-rays change angles, objects within the breasts
change heights, allowing for computer reconstruction. This
technique gives rise to three-dimensional (3D) images that
can be viewed as individual slices or in dynamic cine [60].
Tomosynthesis requires less breast compression time and
pressure than a normal mammogram, providing the patient
greater comfort [60]. Tomosynthesis systems do not require
moving parts near the breast or abdomen, can be used
with minor alterations to existing mammographic systems,
and are able to take conventional mammograms as well
[59]. Tomosynthesis can detect 16% more lesions than can
be seen on a normal mammogram and has been reported
to reduce false-positive results by 85% [61]. Unfortunately,
individual frames contain more noise than normal FFDM
images [62]. Tomosynthesis is starting to be seen in breast
screening centers, but more clinical experience is needed to
determine if it will become a relevant screening test or if it
will become the diagnostic test of choice after a screening
mammogram shows an abnormality. In addition, as Good
et al. [62] note, tomosynthesis requires a signiﬁcant amount
of experience reading and interpreting the images. Without
anFDA approvedbreast tomosynthesis device,a greatdeal of
published sensitivity and speciﬁcity data, or enough clinical
trials to determine its best use, this modality remains at what
Dobbins III [63] refers to as a “translational crossroads”
between the experimental and clinical stages.
3.1.2. Contrast-Enhanced Digital Mammography. Two types
of contrast-enhanced digital mammography are available:
temporal subtraction and dual energy.
In temporal subtraction contrast-enhanced digital mam-
mography, an initial FFDM mask image is obtained, then
a contrast agent (generally iodine-based) is injected intra-
venously, and then multiple X-ray images are obtained [13,
64]. Then the image undergoes temporal subtraction. The
precontrast mask image is subtracted from the postcontrast
image [13, 64].
Indualenergycontrast-enhanceddigitalmammography,
two X-ray images are taken after a contrast agent (generally
iodine-based as well) is injected intravenously. One X-ray
image is high energy, which excites the contrast agent, while
the other is below this excitation threshold [64]. The lower
energy image is then subtracted from the higher energy
image, yielding an X-ray image with greater contrast that is
easier to interpret.
Contrast-enhanced digital mammography has a high
contrast-to-noise ratio, reducing the visibility of microcal-
ciﬁcations [64]. Also, the iodine-based contrast medium
requires a high-energy X-ray. New contrast agents (bismuth-
based for temporal or zirconium-based for dual energy)
could allow for lower energy X-rays, but this result would
involve development of a contrast agent used exclusively for
mammograms, which is expensive [64]. Also, the subtrac-
tion process may lead to the appearance of artifacts [64].6 International Journal of Biomedical Imaging
Contrast-enhanced digital mammography can be combined
with tomosynthesis. Known as contrast-enhanced digital
breasttomosynthesis,thistechnologyhasnotyetbeenexten-
sively tested. One study by Chen et al. [65] proposes that
these two techniques can be combined, thereby uniting the
strengths of each method, to characterize the morphologic
and vascular natures of breast lesions. This technology
is sensitive to motion, but motion can be decreased by
decreasing the length of the procedure [65]. A great deal
more work needs to be done in the development of this
tool.
3.2. Advanced Applications of Ultrasound
3.2.1. Sonoelastography. In sonoelastography (SE), ultra-
sound images are taken while breast tissue is displaced.
Displacement methods include compression, vocal fremitus
low-frequency vibrations (the patient hums a pitch), and
radiation force [15, 23]. Breast tissues vibrate or compress
diﬀerently based on their ﬁrmness, which permits one to
locate masses. Researchers have reported varying results.
Some indicate positive results; others conclude that the
performance of SE is worse than that of conventional US
[23, 66].
3.2.2. Tissue Harmonic Imaging. Tissue harmonic imaging
(THI) has two types: narrowband and wideband. In nar-
rowband THI, ﬁlters remove the fundamental frequency
from echoed harmonics resulting from a narrowband pulse.
In wideband THI, two inverted pulses are emitted and
added together, removing linear components when they
return upon echo [67]. Szopinski et al. [67] found that
THI increased gray-scale contrast between fatty tissue and
breast lesions in 90.6% of 254 lesions. This improvement
in contrast was better in fattier breasts [67]. Other studies
indicate that THI may contain data not obtained using B-
mode US, suggesting uses other than image enhancement
[23].
3.2.3. Ultrasonic Spiral Computed Tomography. As t u d yb y
Azhari and Sazbon [68] suggests that ultrasonic spiral
computed tomography (CT), a cross between CT and US, is
a feasible form of volumetric 3D imaging. This technology is
suitablealmost exclusively for breastimaging; however, it has
diﬃculty in detecting tumors located proximal to the chest
wall [68].
3.3. Advanced Applications of MRI
3.3.1. Diﬀusion and Perfusion Imaging. Diﬀusion and perfu-
sion imaging, two emerging forms of MRI, show promise
in characterizing breast tumors. Diﬀusion imaging oﬀers
information concerning tissue microstructure by focusing
on water protons [69]. Perfusion imaging follows the ﬂow
of blood to tissue, showing the microvasculature [69].
Research shows that the values of the apparent diﬀusion
coeﬃcient and the relative tissue blood volumes permit one
to distinguish between malignant and benign lesions [69].
3.3.2. Proton Magnetic Resonance Spectroscopy. Proton mag-
netic resonance (MR) spectroscopy (1H-MRS) measures the
resonance of protons to provide a spectrum. With this data
it can identify a peak of choline, a biomarker of cancer, at
3.23ppm as opposed to 3.28ppm in benign breast lesions
[70]. Sardanelli et al. [71]f o u n d1H-MRS to have a 90%
sensitivity rate and an 89% speciﬁcity rate, indicating a
higher speciﬁcity than dynamic MRI. A similar method,
31P MR spectroscopy, has also been studied, displaying an
increase in phosphomonoesters in breast cancer tissue but
with a poor ability to distinguish between malignant and
benign tissues [71]. With lipid and water suppression, this
technology could be used to gain information about breast
tumors. Indeed, the software is now widely available on the
newest MRI machines.
3.3.3. MR Elastography. In MR elastography, electromechan-
ical drivers vibrate the breast, generating acoustic shear
waves, which are then imaged by MRI [72]. Through this
process, stiﬀness can be measured. McKnight et al. [72]
found that breast carcinoma displayed a mean shear stiﬀness
that was 418% greater than that of surrounding breast tissue.
This method could be used in the future for the detection,
and perhaps characterization, of breast cancer.
3.4. Computed Tomography. An e wf o r mo fC Th a sb e e n
created at the University of California, Davis Medical Center
speciﬁcally for breast scanning. The 360◦ scan, which takes
16.6 seconds, obtains about three hundred 512 ×512 images
of each breast, creating 3D images [73] that allow analysis
by the slice. This technology requires no breast compression
because of its speciﬁc design. Also, CT images do not
experience the distortion seen in MRI, and regular biopsy
needles can be used [73]. An algorithm has been created
that classiﬁes breast tissue as skin, fat, and glandular tissue.
With this algorithm, Nelson et al. [74]w e r ea b l et od i s p e l
the common perception that the breast is composed of 50%
fat and 50% glandular tissue; rather it is approximately 70%
fat and 30% glandular tissue. This algorithm showed 97.7%
agreement with the ﬁndings of a radiologist [74].
W h e r e a sn o r m a lC Ts u b j e c t st h ec h e s to r g a n so fp a t i e n t s
to radiation, this speciﬁed CT does not; in fact, its average
glandular dose of radiation is 6.4mGy per breast, which is
not much more than that of a two-view mammogram [74].
CT scanning can be enhanced using iodine-based contrast
agents (similar to the aforementioned). The contrast of
CT images can also be heightened by diﬀraction-enhanced
imaging (DEI), which, after lowering the radiation dose
of current trials, could be used clinically [75]. Boone et
al. [73] predicted that tomosynthesis, which uses a limited
angle to create a thick slice image, will “outperform breast
CT for microcalciﬁcation detection, while breast CT will
likely outperform tomosynthesis for soft tissue (mass) lesion
detection.” Boone and colleagues [73] also estimated that
breast CT will cost less than half the price of an MRI-
based biopsy. CT requires its subject to remain still, while
holding her breath for the duration of the scan. A move
towarda9-secondscan,asproposedbyBooneandcolleaguesInternational Journal of Biomedical Imaging 7
Table 2: Results of PEM studies. NPV: negative predictive value; PEM: positron emission mammography; PPV: positive predictive value.
Study Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%) Number of lesions
Berg et al. [78]9 1 9 3 9 5 8 8 9 2 9 2
Rosen et al. [77]∗ 86 33 90 25 — 20
Levine et al. [58]8 6 9 1 — — 8 9 1 8
∗Low values due to small number of true negative cases.
[73], should reduce patient discomfort and the appearance
of motion artifacts. Other research has looked into cone-
beam volume CT breast imaging, a technology that uses
a rotating X-ray to scan one breast at a time while it
hangs through a hole in a table [76]. This technology
also delivers an amount of radiation comparable to that
from a normal mammogram and obtains a 3D image with
much greater contrast than a normal mammogram. This
approachmayimproveimagingwithoutincreasingradiation
exposure and without compression, but it will not reduce
the cost or improve the access to screening associated with
mammography.
3.5. Advanced Applications of Nuclear Medicine
3.5.1. Positron Emission Mammography. Am o r eb r e a s t -
speciﬁc PET technique known as positron emission mam-
mography (PEM) or breast-speciﬁc gamma imaging focuses
on imaging the breasts rather than the entire body. PEM
costs less than conventional PET [43]. It has higher spatial
resolution [43, 77], requires a lower dose of FDG [77], and
t a k e sl e s st i m et op e r f o r m[ 77]. PEM has also been reported
to be better at detecting DCIS and small cancers than other
nuclear medicine techniques [78, 79]. Still, one encounters
diﬃculty imaging the far posterior area of the breast, and
the technique suﬀers from high false-positive rates due to
fat necrosis at prior biopsy locations [77]. PEM is best
for screening high-risk patients [79]. Data concerning this
technique are summarized in Table 2.
3.5.2. PET/CT. The PET and CT systems have recently been
combined, allowing for both imaging techniques without
repositioning the patient [53]. This modality costs more
than each individual system yet requires less time to acquire
anatomical and molecular data simultaneously [53, 80]. A
recent study, using 18F-FDG PET/CT for axillary staging,
found that the technology had an 83% accuracy, 58%
sensitivity, and 95% speciﬁcity; despite its limited sensitivity,
its diagnostic accuracy is comparable to that of US [81]. At
present, no studies of PET/CT as a screening modality exist.
3.6. Diﬀraction Techniques
3.6.1. Diﬀraction-Enhanced Imaging. In DEI, a crystal, called
the analyzer crystal, is placed between the object and the
detector (digital or X-ray ﬁlm) based on Bragg geometry.
A synchrotron delivers a monoenergetic beam through the
object and delivers two images on either side of the rocking
curve by changing the angle of the analyzer [82]. The images
contain the same apparent absorption data and opposite
refraction data. By applying an algorithm, adding pixel by
pixel, an apparent absorption image (similar to that of a
normal X-ray) can be obtained; by subtracting pixel by pixel,
a refraction image can be obtained [83]. A peak image can
also be obtained, which is recorded at the peak of the rocking
curve [83]. Breast tissue microstructures are seen with the
best clarity and contrast in refraction images, followed by
peak images, and then apparent absorption images [83].
DEI requires a short exposure time and has higher
spatial resolution than B-mode ultrasonography, MRI, and
CT [83]. Though DEI images are clearer using X-ray ﬁlm
and viewed by an optical microscope, it is more suitable to
use digital media [83]. One study of seven cases found that
six (86%) showed “enhanced visibility of surface speculation
that corresponded with histopathologic information” [84].
Another study, performed by Kiss et al. [85], showed that
DEI improved contrast of calciﬁcations by a factor of 19.
Studies suggest that with improvements, such as enabling
compatibility with usual X-ray sources, DEI should move
toward clinical use, detecting early stage breast cancer such
as DCIS [83, 85].
3.6.2. Small-Angle X-Ray Scattering. Small-angle X-ray scat-
tering (SAXS) uses the coherent scattering obtained at small
angles (between 3◦ and 10◦) to classify tissues [86]. This
technique can identify structures as small as 0.1nm [87,
88]. SAXS can identify collagen ﬁber patterns, which are
related to the spread of cancer. Changizi and colleagues
[86] reported the ability to diﬀerentiate between normal,
benign, and malignant breast tissues. Also, Round et al.
[89] found 100% sensitivity associated with SAXS, although
from a small sample size. SAXS, once it becomes compatible
with conventional X-ray sources, could be used as a clinical
diagnostic tool to microscopically image areas of concern in
vivo, obviating the need for tissue biopsy [89]. One study
suggests that a combination of SAXS and DEI could be used
as a diagnostic tool [87].
3.7. Raman Spectroscopy. In the inelastic scattering process
known as Raman spectroscopy, a laser is used to excite
photons,causingenergytransfersbetweenvibrationalmodes
[90]. The optimum wavelength for this type of spectroscopy
is near infrared, from 785nm to 840nm [91]. The Raman
spectra peaks correspond to diﬀerent molecules. Whereas
normalmammaryspectraprimarilycontainpeaksassociated
with lipids, tumor-containing mammary glands show an
increase in peaks, indicating proteins, and a decreasein those
indicating lipids [90, 92].8 International Journal of Biomedical Imaging
Raman spectroscopy is accurate, displaying an ability
to identify 91% of tumor spectra correctly [92]. It is
noninvasive and can be performed in real time inexpensively
whileconsumingverylittletime[92,93].Also,resultsarenot
signiﬁcantly aﬀected by breast density or menopause [90].
Raman spectroscopy can also detect preneoplastic changes
by detecting chemical changes in the tumor bed [92]. One
common form of Raman spectroscopy is spatially oﬀset
Raman spectroscopy (SORS), which uses backscattering to
identify individual components in the sample [93]. Recent
work by Stone and Matousek [91, 93] has focused on
transmission Raman spectroscopy rather than SORS. This
technique cannot be used to identify the depth of the
tumor yet it can be used to identify calciﬁed material
and classify its composition at greater depths than SORS
[93], a maximum depth so far of 2.7cm using a dielectric
ﬁlter in a phantom breast made of porcine tissues [91].
Transmission Raman spectroscopy can be used together
with SORS, ultrasonography, or mammography to locate
calciﬁcations. Raman spectroscopy shows potential for rapid
breast cancer detection in tissue samples and, perhaps even-
tually with improvements, as an adjunct to other screening
modalities.
3.8. Diﬀuse Optical Imaging. Diﬀuse optical imaging (DOI),
or optical mammography (OM), uses near infrared light
to detect functional abnormalities in tissue [94]. Detected
properties, many of which are linked to angiogenesis and
hypoxia, include hemoglobin concentration, blood oxygen
saturation, water content, and lipid content [94, 95]. About
85% of breast lesions can be discovered using DOI [94]. This
technique is “non-invasive, non-ionizing, low-cost...[and]
requires little or no breast compression” [94].
DOI comprises two types: transillumination and tomo-
graphic. In transillumination DOI, the detectors lie opposite
the sources with the breast residing in the middle, resulting
in 2D images [94]. In diﬀuse optical tomography (DOT), a
3D map is obtained through sources and detectors placed on
the surface of the breast at diﬀerent angles [94, 95].
DOI methods can be improved by the use of contrast-
enhancing agents. The most commonly used agent is
indocyanine green, which is a safe near infrared-absorbing
ﬂuorescent dye [94, 95]. DOI can also be improved by
adding sound through the processes of acousto-optical
tomography (AOT), also known as ultrasound-modulated
optical tomography, and photoacoustic tomography (PAT),
also known as optoacoustic or thermoacoustic tomography.
These methods add the resolution advantage of ultrasound
to the contrast advantage of optical imaging [96]. An
ultrasound wave is sent into the tissue in AOT; whereas
in PAT ultrasonic transducers measure photoacoustic waves
that have been excited by a laser [96] .T h e s et e c h n i q u e sc a n
aid molecular and functional imaging.
DOI shows promise for detecting cancers early, based on
molecularchanges.DOIisperformedthroughthreediﬀerent
types of systems: time domain, frequency domain, and
continuous wave. From the data acquired by these methods,
algorithms create images, whether 2D or 3D.
3.8.1. Time Domain. Time domain (TD) systems use
picosecond pulses of light shone upon the breast, which are
detected as they exit [94]. The temporal distribution (time
of ﬂight) is measured, and properties of the tissue can be
determined from this distribution [94, 97]. This process can
be bettered through time-gating [97]. The equipment used
in this technique is expensive [94, 97].
3.8.2. Frequency Domain. Frequency domain (FD) systems
continuously shine light on the breast while the amplitude of
its frequency is modulated by tens to hundreds of megahertz
[94]. Amplitude decay and phase-shift measurements pro-
vide information concerning the tissue’s properties [94, 97].
3.8.3. Continuous Wave. Continuous wave (CW) systems
determine tissue properties measuring the attenuation of
light across the breast [94]. This light is delivered continu-
ously at a constant or low frequency modulated amplitude
[94]. Although this method is cheaper and simpler than TD
and FD, it cannot determine the internal absorption and
scattering properties, and it is very sensitive to variation in
surface coupling [94, 97].
3.9. Electrical Impedance Scanning. Electrical impedance
scanning (EIS), also known as electrical impedance tomog-
raphy(EIT),measuresmultipleelectricalpropertiesofbreast
tissue and creates an image. It is meant for discovering
nonpalpable lesions [98] .T h ec e l lm e m b r a n ei sp r i m a r i l y
capacitive but displays conductivity in its semipermeable
function. EIS measures conductance at low frequencies
(<1000Hz)andcapacitanceathigherfrequencies[99].These
properties factor into the impedance value. Most EIS systems
operate at high frequencies because, at low frequencies,
electrode impedances aﬀect the constant nature of the input
current [100]. Cancerous and normal tissues have diﬀerent
electrical properties, yet the values overlap at a point [99].
Many electrical impedance scans have been performed
using the Siemens TransScan TS2000 and TS2000ED (Early
Detection). A similar system is used at Dartmouth College.
The systems work by sending a current into the breast and
measuring voltages at electrodes placed on the surface. The
measurements are then analyzed by a computer algorithm.
EIS is noninvasive, relatively inexpensive, and risk free [98,
100, 101]. Scans usually take about 15 minutes, causing the
patient little discomfort. It can be performed in vivo or in
vitro, though in vitro measurements must be made soon
after the death of the tissue [99]. Unlike mammograms, EIS
works well with dense breasts. It has also been shown to
detectextremelysmalllesionsthatothermethodsmightmiss
[102]. These scans are subject to variation caused by the
patients’ hormonal changes as well as other factors including
“superﬁcial skin lesions, poor contact, and air bubbles”
[103].
Though hopes were high for EIS, studies show con-
tradictory results. Although Kneeshaw et al. [104]f o u n d
that “EIS is able to diﬀerentiate malignant from benign
disease associated with clinically occult microcalciﬁcation,”
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scan “mediocre.” Melloul et al. [102] decided that EIS, with
its 72.2% sensitivity and 67% speciﬁcity, did not improve
the detection rate of breast cancer when combined with
99mTc-SSM. In another study, EIS yielded a false-positive
ratecomparablewiththatofmammography[106].Similarly,
Szab´ oetal.[107]couldnotjustifytheuseofEISasanadjunct
to mammography and ultrasonography; the 86% sensitivity
of the TransScan TS2000 was similar to the 87% and
75% sensitivities of mammography and ultrasonography,
respectively.
The technology yields images with spatial resolution
poorer than that of CT and MRI and “has an intrinsically
poor signal-to-noise ratio” [100]. Another detriment is
the parasitic capacitances related to the input leads [100].
It was recently found that EIS identiﬁes general breast
abnormalities, which can show which women are at risk of
developing cancer in the future [108]. Stojadinovic et al.
[98] noted that the TS2000ED system “seems better suited
to identify women at a high risk of breast cancer, in the
absence of a speciﬁc lesion that can be localized.” In a
later study, in which they found 38% sensitivity and 95%
speciﬁcity, they furthered this statement by recommending
that this technology should be used for screening rather than
detection or imaging [101].
Halter et al. [109] recently designed an EIS system that
uses very high frequencies (as high as 10MHz) that can
measure impedances with an accuracy of 99.7%. At these
frequencies, other properties may be measured. Still, further
study is needed to determine the beneﬁt of EIS.
3.10. Thermography. In thermography, an infrared scan cre-
ates an image by mapping temperature diﬀerences across the
breasts. Because cancerous tumors obtain nutrients through
neoangiogenesis and through already existing blood vessels,
the local temperature of the cancerous region is generally
higher than that of surrounding tissue [110, 111]. Because
“each breast has a particular thermographic pattern than
does not change over time, much like a ﬁngerprint,” one can
takeabaselineandmarkanysigniﬁcantchangesseenonlater
images for future analysis [110]. Generally, the procedure
consists of taking a series of infrared photographs of the
breasts while one breast is cooled. The procedure is then
repeated, cooling the other breast. After imaging, the data
are analyzed by computer algorithms that compare infrared
patterns.Theprocedure,includingtheimagingprocess,takes
about 15 minutes [112]. Thermographic systems include the
BCS2100 and the BreastScan IR.
Infrared thermography has many potential beneﬁts. It is
a noninvasive process that consumes minimal time. In one
study, Parisky et al. [112] used the BCS2100, ﬁnding 97%
sensitivity, 14% speciﬁcity, 95% negative predictive value,
and 24% positive predictive value in a group of 875 subjects,
and 99% sensitivity, 18% speciﬁcity, 99% negative predictive
value,and27%positivepredictivevalueinasubsetexcluding
lesions deemed to be microcalciﬁcations. In another study,
Arena et al. [113] found 98% sensitivity in a study of 67
patients with cancer proven by biopsies.
Thermography works better in certain situations. Imag-
ing is best performed when the female body temperature
is most stable: the ﬁfth, twelfth, and the twenty-ﬁrst days
of menstruation [110]. Also, speciﬁcity increases when the
breast tissue is dense rather than fatty. Larger tumors are
more often detected by infrared imaging [114]. This method
of detection has its disadvantages. Images are adversely
aﬀected by procedural errors, including the amount of
cooling and the breast positioning [112]. Larger breasts and
dependent areas of the breasts are poorly imaged. Also, if
the patient has an asymmetrical body temperature, analysis
could result in false-negative and false-positive results. Other
limitations include the large size of the computer ﬁles and
the variations due to age, tumor position, and the afore-
mentioned hormones. Still, this method shows promise for
detecting cancer in patients, such as “younger women, men,
patients with dense breasts, [and] patients with surgically
altered breasts,” that are troublesome for other detection
modalities [115].
3.11. Compression and Palpation Method. A good clinical
breast exam has a high speciﬁcity, that is, about 97%.
The sensitivity is, however, low because one is unable to
palpate small tumors, deep tumors, and microscopic DCIS.
The basis of tumor detection and identiﬁcation in CBE is
the fact that malignancies have diﬀerent elastic and sheer
moduli related to the surrounding tissue. Researchers have
looked into compression and palpation methods to detect
breast cancer. Yegingil et al. [116] created a piezoelectric
ﬁnger (PEF), a sort of cantilever system, consisting of a
stainless steel prod between a top layer of piezoelectric
lead zirconate titanate (PZT) for driving and a bottom
layer of PZT for sensing. An electric ﬁeld is applied to the
driving PZT layer, causing the ﬁnger to bend. The bend
induces a voltage across the sensing PZT layer, which is
then measured, indicating the displacement. The PEF can
measure compression, indentation, shear, and indentation
shear, giving the elastic and shear moduli and therefore
Poisson’s ratio as well [117]. This system can show the size
and location of tumors through moduli maps [117]. This
systemcanalsodeterminethedepthofthetumor[118].This
system and its measured moduli are modeled in Figure 1.E x
vivotestingonhumanbreasttissuesamplesresultedin100%
sensitivity and 59% speciﬁcity for the detection of breast
cancers and DCIS. In vivo human trials are expected within
ay e a r .
ThePEFhasthepotentialbeneﬁtsoflowcost,portability,
results that do not have to be read by a radiologist, and a
system that is not user dependent.
A similar system produced by Medical Tactile Inc (Los
Angeles,CA),calledSureTouch,alsomechanicallyimagesthe
breast. This system consists of a probe with a 2D pressure
sensor array and an electronic unit that connect to a laptop
c o m p u t e rv i aaU S Bp o r t[ 119]. With the software, one can
visualize the 2D pressure pattern, the total applied force,
and the breast nodule cross-sectional views in real time
[119]. The technology has two modes: one for detecting
areas of concern and another for characterization [119]. The
system works better with a lubricating gel (similar to manual
palpation methods) and can detect inclusions farther from10 International Journal of Biomedical Imaging
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Figure 1: (a) Measured moduli; (b) the piezoelectric ﬁnger system. PZT: piezoelectric lead zirconate titanate.
the breast surface than a human ﬁnger can [119]. It loses
reliability when palpating deep lesions in large breasts or
mobile lesions in soft breasts, but, considering its “low cost,
ease-of-cost, portability, and minimal training required,”
the SureTouch system shows potential for clinical or even
personal home use [119].
3.12. Hair Diﬀraction. Recent studies indicate that X-ray
diﬀraction of hair could detect breast cancer at a stage earlier
than that detectable by mammography [120]. Changes in
hair structure, speciﬁcally the α-keratin ﬁbers that make
up the intermediate ﬁbers of hair, display patterns that
correspond to those of breast cancer as well as other diseases
[120].
Research by James [120]shows100%sensitivityand92%
speciﬁcity.Herﬁndingswereconﬁrmed,althoughwithlower
sensitivity values, by Corino and French [121].
Requiring only ten hairs, this technique is noninvasive
and works with women of all ages [120, 121]. Hairs must be
undamaged—slight defects in the hair strands could aﬀect
results [120, 121]. Though it cannot locate or image tumors,
thistechniqueshowspromiseasanoninvasivescreeningtool.
A great deal of work remains to be done before it can be used
clinically.
3.13. Breath Detection. Patients with breast cancer also
undergo increased oxidative stress and induction of poly-
morphic cytochrome P-450 mixed oxidase enzymes, aﬀect-
ing the amount of volatile organic compounds (VOCs)
found in the breath [122]. Phillips and colleagues [122]
performed breath tests using gas chromatography and mass
spectroscopy, ﬁnding them to have 94.1% sensitivity and
73.8% speciﬁcity for determining the presence of breast
cancer compared with results from healthy subjects. In
women with abnormal ﬁndings on their mammograms but
with no cancer detected through biopsy, Phillips et al. [122]
found the test to have a sensitivity of 62.7% and a speciﬁcity
of 84%. This study also reported that breath detection has
a negative predictive value of 99.93%, which is higher than
that of mammography (99.89%), yet a positive predictive
value lower than that of mammography: 4.63% compared
to 1.29% [122]. Their data were not aﬀected by patient
smoking status [122]. Results indicate that breath detection
could help screen for patients with breast cancer without
imaging.
3.13.1. Canine Scent Detection. In a recent study by McCul-
loch and colleagues [123], dogs were trained to detect
breast and lung cancer through breath scent, noting that
gas chromatography and mass spectroscopy may not be able
to ﬁnd all cancer-related chemicals. The study found 88%
sensitivity and 98% speciﬁcity in detecting breast cancer and
higher values in detecting lung cancer [123]. Though more
research is needed, this study shows promise in using canines
to screen for cancers. Another study proposed that dogs may
also be able to detect the presence of cancer through urine
scent [124]; however, the results of this trial were negative.International Journal of Biomedical Imaging 11
4. Conclusion
Breast cancer is a global problem. It comprises 27% of new
cases of cancer in women [2]. With the opportunity for early
detection, more lives can be saved. We have summarized
the current state of the art in breast cancer screening
and early detection. In addition, we have highlighted some
emerging technologies that may augment or replace the
current modalities.
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